NCT00011895Unknown4 期
A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects
适应症
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 400
- 试验地点
- 42
研究概览
简要总结
The purpose of this study is to determine the effect of treatment with Trizivir (TZV) plus efavirenz (EFV) or TZV alone on viral load (level of HIV in the blood).
详细描述
Patients receive TZV plus EFV in the 48-week Induction Phase. Eligible patients, defined as those with plasma HIV-1 RNA under 50 copies/ml, participate in the 48-week Maintenance Phase. Patients are randomized equally to receive either TZV plus EFV or TZV alone.
An immunology substudy will be conducted, including approximately the first 100 patients enrolled who agree to participate.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are at least 13 years old.
- •Are HIV-positive.
- •Have a viral load of at least 5,000 copies/ml.
- •Agree to use adequate and reliable methods of birth control. Note: Hormonal birth control is not considered adequate.
- •Provide written consent of a parent or guardian, if under 18 years of age.
排除标准
- •Patients will not be eligible for this study if they:
- •Have taken nonnucleoside reverse transcriptase inhibitors.
- •Have taken other anti-HIV drugs for 2 weeks or more.
- •Have an opportunistic (AIDS-related) infection.
- •Are pregnant or breast-feeding.
- •Have had hepatitis within the past 6 months.
- •Are allergic to the study drugs or their ingredients.
- •Have a mental, physical, or substance abuse disorder.
- •Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease.
- •Have a gastrointestinal disorder that affects drug absorption or makes it difficult to take medication by mouth.
- •Have received within 4 weeks before study entry, or may require during the study period, radiation therapy, chemotherapy, or drugs that affect the immune system (such as steroid drugs, interleukins, vaccines, or interferons).
- •Have received an HIV vaccine within 3 months before study entry, or are scheduled to receive one during the study period.
- •Require foscarnet or other drugs that are shown to be effective against HIV.
- •Are taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives.
- •Are taking experimental drugs.
- •Are unlikely to complete the study or take the drugs.
研究者
研究点 (42)
Loading locations...
相似试验
Unknown
3 期
Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)HIV InfectionsNCT00004981Glaxo Wellcome230
已完成
4 期
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System SymptomsHIVNCT02529059St Stephens Aids Trust40
已完成
1 期
VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy VolunteerAIDSHIVHCVHepatitis CNCT00828789Tibotec BVBA20
终止
3 期
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B InfectionChronic Hepatitis BNCT00605384Bristol-Myers Squibb4
Unknown
2 期
Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus PneumoniaNovel Coronavirus PnuemoniaNCT04319900Beijing Chao Yang Hospital150